

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal615lxc

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 18 Current-awareness alerts, saved answer sets, and current
search transcripts to be affected by CERAB, COMPUAB, ELCOM,
and SOLIDSTATE reloads
NEWS 6 NOV 30 PHAR reloaded with additional data
NEWS 7 DEC 01 LISA now available on STN
NEWS 8 DEC 09 12 databases to be removed from STN on December 31, 2004

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:52:26 ON 14 DEC 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:52:32 ON 14 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2004 HIGHEST RN 796963-46-7

DICTIONARY FILE UPDATES: 13 DEC 2004 HIGHEST RN 796963-46-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> e nefazodone

E1	5	NEFAZO/BI
E2	5	NEFAZOD/BI
E3	5 -->	NEFAZODONE/BI
E4	2	NEFCO/BI
E5	3	NEFD124G/BI
E6	7	NEFD125G/BI
E7	1	NEFD125G0MYR/BI
E8	1	NEFDELTAMHCDELTA4/BI
E9	1	NEFDMHCDCD4/BI
E10	1	NEFEDOVITE/BI
E11	1	NEFEIN/BI
E12	1	NEFENCH/BI

=> e3

L1 5 NEFAZODONE/BI

=> s l1

L2 5 NEFAZODONE/BI

=> d l2

L2 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2004 ACS on STN

RN 153707-86-9 REGISTRY

CN 3H-1,2,4-Triazol-3-one, 5-acetyl-2-[3-[4-(3-chlorophenyl)-1-
piperazinyl]propyl]-2,4-dihydro-4-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Oxonefazodone**

FS 3D CONCORD

MF C25 H30 Cl N5 O3


CI COM

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> dl3

L4 1 DL3

=> d l3

L3 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN

RN 96860-46-7 REGISTRY

CN 9,10-Ethanoanthracen-2-ol, 9-(3-aminopropyl)-9,10-dihydro- (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 2-Hydroxydesmethylnaprotiline


FS 3D CONCORD

MF C19 H21 N O

LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Journal

RL.NP Roles from non-patents: PROC (Process)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:191227 CAPLUS

DOCUMENT NUMBER: 130:277915

TITLE: A controlled trial of **sustained-release bupropion**, a nicotine **patch**, or both for smoking cessation

AUTHOR(S): Jorenby, Douglas E.; Leischow, Scott J.; Nides, Mitchell A.; Rennard, Stephen I.; Johnston, J. Andrew; Hughes, Arlene R.; Smith, Stevens S.; Muramoto, Myra L.; Daughton, David M.; Doan, Kimberli; Fiore, Michael C.; Baker, Timothy B.

CORPORATE SOURCE: Center for Tobacco Research and Intervention, University of Wisconsin Medical School, Madison, WI, USA

SOURCE: New England Journal of Medicine (1999), 340(9), 685-691

CODEN: NEJMAG; ISSN: 0028-4793

PUBLISHER: Massachusetts Medical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI A controlled trial of **sustained-release bupropion**, a nicotine **patch**, or both for smoking cessation

AB Use of nicotine-replacement therapies and the antidepressant **bupropion** helps people stop smoking. We conducted a double-blind, placebo-controlled comparison of **sustained-release bupropion** (244 subjects), a nicotine **patch** (244 subjects), **bupropion** and a nicotine **patch** (245 subjects), and placebo (160 subjects) for smoking cessation. Smokers with clin. depression were excluded. Treatment consisted of nine weeks of **bupropion** (150 mg a day for the first three days, and then 150 mg twice daily) or placebo, as well as eight weeks of nicotine-**patch** therapy (21 mg per day during weeks 2 through 7, 14 mg per day during week 8, and 7 mg per day during week 9) or placebo. The target day for quitting smoking was usually day 8. The abstinence rates at 12 mo were 15.6 percent in the placebo group, as compared with 16.4 percent in the nicotine-**patch** group, 30.3 percent in the **bupropion** group ($P<0.001$), and 35.5 percent in the group given **bupropion** and the nicotine **patch** ($P<0.001$). By week 7, subjects in the placebo group had gained an average of 2.1 kg, as compared with a gain of 1.6 kg in the nicotine-**patch** group, a gain of 1.7 kg in the **bupropion** group, and a gain of 1.1 kg in the combined-treatment group ($P<0.05$). Weight gain at seven weeks was significantly less in the combined-treatment group than in the **bupropion** group and the placebo group ($P<0.05$ for both comparisons). A total of 311 subjects (34.8 percent) discontinued one or both medications. Seventy-nine subjects stopped treatment because of adverse events: 6 in the placebo group (3.8 percent), 16 in the nicotine-**patch** group (6.6 percent), 29 in the **bupropion** group (11.9 percent), and 28 in the combined-treatment group (11.4 percent). The most common adverse events were insomnia and headache. Treatment with **sustained-release bupropion** alone or in combination with a nicotine **patch** resulted in significantly higher long-term rates of smoking cessation than use of either the nicotine **patch** alone or placebo. Abstinence rates were higher with combination therapy than with **bupropion** alone, but the difference was not statistically significant.

ST **bupropion** nicotine **patch** smoking cessation

IT Tobacco smoke

(addiction; controlled trial of **sustained-release bupropion** or nicotine **patch** or both for smoking

cessation in humans)

IT Drug interactions
 (controlled trial of **sustained-release**
bupropion or nicotine **patch** or both for smoking
 cessation in humans)

IT Drug delivery systems
 (controlled-release; controlled trial of **sustained-**
release bupropion or nicotine **patch** or both
 for smoking cessation in humans)

IT Drug dependence
 (smoking; controlled trial of **sustained-release**
bupropion or nicotine **patch** or both for smoking
 cessation in humans)

IT Drug delivery systems
 (tapes; controlled trial of **sustained-release**
bupropion or nicotine **patch** or both for smoking
 cessation in humans)

IT 54-11-5, Nicotine 34911-55-2, **Bupropion**
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BSU (Biological study, unclassified); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (controlled trial of **sustained-release**
bupropion or nicotine **patch** or both for smoking
 cessation in humans)

=>

=> d his full

(FILE 'HOME' ENTERED AT 16:40:35 ON 14 DEC 2004)

FILE 'CAPLUS' ENTERED AT 16:40:45 ON 14 DEC 2004

FILE 'REGISTRY' ENTERED AT 16:40:50 ON 14 DEC 2004

E BUPROPION

L1 9 SEA ABB=ON PLU=ON BUPROPION/BI
D L1

FILE 'CAPLUS' ENTERED AT 16:42:03 ON 14 DEC 2004

L2 0 SEA ABB=ON PLU=ON TOPICAL (P) BUPROPION

L3 31 SEA ABB=ON PLU=ON (TOPICAL OR PATCH OR GEL OR LOTION OR
CREAM OR AEROSOL OR OINTMENT) (P) BUPROPION

L4 38 SEA ABB=ON PLU=ON (TOPICAL OR PATCH OR GEL OR LOTION OR
CREAM OR AEROSOL OR OINTMENT) (P) (BUPROPION OR REBOXETINE OR
MAPROTILINE)
D 30-38 IBIB KWIC 1-

L5 0 SEA ABB=ON PLU=ON L4 AND NEUTRALIZING AGENT

L6 0 SEA ABB=ON PLU=ON L4 AND (SUSTAINED RELELASE OR SLOW
RELELASE OR LIPOSOME OR MICROCAPSULE OR POLYMER STABILIZED
CRYSTAL OR NEUTRALIZER)

L7 11 SEA ABB=ON PLU=ON L4 AND (SUSTAINED RELEASE OR SLOW RELEASE
OR LIPOSOME OR MICROCAPSULE OR POLYMER STABILIZED CRYSTAL OR
NEUTRALIZER)
D L7 IBIB 1-

FILE 'STNGUIDE' ENTERED AT 16:50:15 ON 14 DEC 2004

FILE 'CAPLUS' ENTERED AT 16:50:34 ON 14 DEC 2004

FILE 'STNGUIDE' ENTERED AT 16:50:39 ON 14 DEC 2004

FILE 'CAPLUS' ENTERED AT 16:50:48 ON 14 DEC 2004

D L7 11 IBIB KWIC